Plain-English translation of NCT07462507 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new imaging scan called PET to help doctors better understand and monitor brain tumors. The scan works by highlighting areas of inflammation and disease activity in the brain, which may help doctors see how well treatment is working and detect changes in the tumor more clearly. Researchers believe this new imaging approach could provide helpful information that routine scans don't currently show.
Current imaging methods don't always show doctors everything they need to know about how brain tumors are responding to treatment or how active they are. This medication is designed to fill that gap by highlighting inflammation and tumor activity in ways that standard scans cannot, potentially helping doctors make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
You will come to the hospital or imaging center for a baseline scan, where you'll receive an injection of the imaging tracer and then lie still for up to 90 minutes while the PET scanner takes pictures of your brain. You may be invited back for a follow-up scan within 6 months to 2 years after your cancer treatment, so doctors can compare how the images change over time. Your regular cancer care and treatment decisions will not be affected by this study—the scans are done in addition to your normal medical imaging.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States